Skip to main content
. Author manuscript; available in PMC: 2016 Feb 12.
Published in final edited form as: J Neurooncol. 2014 Sep 12;121(1):91–100. doi: 10.1007/s11060-014-1612-1

Fig. 5.

Fig. 5

Axitinib treatment of 005 GSC-derived intracerebral tumors. a Survival of mice with syngeneic 005 intracranial tumors treated with control (n = 6) or axitinib (n = 8). Axitinib significantly increased survival (p = 0.0001, Log-rank (Mantel-Cox) test). Red bracket indicates time of 23 days treatment. b Immunohistochemistry for CD34 (brown) in intracerebral 005 tumors treated with control (left) or axitinib (right). Original magnification, ×200. Scale bars, 50 μm